Original filing text · Part I

Item 3 — Quantitative and Qualitative Disclosures About Market Risk

Nurix Therapeutics, Inc. · 10-Q · Q2 FY2026 · Period ended May 31, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

Our market risks, as of May 31, 2026, have not changed materially from those discussed in “Item 7A. Quantitative and Qualitative Disclosures About Market Risk” of Part II of our Annual Report on Form 10-K for the year ended November 30, 2025, filed with the SEC on January 28, 2026.